about
Ipilimumab: from preclinical development to future clinical perspectives in melanoma.The effect of various vitamin D supplementation regimens in breast cancer patients.Lung cancer in the very elderly: incidence, presentation, and diagnostic decision-making. A retrospective analysis at a teaching community hospitalOvarian cancer from an immune perspective.Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease: A Report of 2 Patient CasesSpotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapyIMCT-21UPDATES ON PHASE 1B/2 COMBINATION STUDY OF THE IDO PATHWAY IHIBITOR INDOXIMOD WITH TEMOZOLOMIDE FOR ADULT PATIENTS WITH TEMOZOLOMIDE-REFRACTORY PRIMARY MALIGNANT BRAIN TUMORS.Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study.Quality-of-life outcomes in patients with advanced melanoma: A review of the literature.Acute Flare of Bullous Pemphigus With Pembrolizumab Used for Treatment of Metastatic Urothelial Cancer.Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development.Understanding Microbiome Effect on Immune Checkpoint Inhibition in Lung Cancer: Placing the Puzzle Pieces TogetherInhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyondNon-Muscle Invasive Papillary Urothelial Carcinoma Metastatic to the MandibleIndoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in CancerAutoimmune retinopathy and optic neuropathy associated with enolase-positive renal oncocytomaCurrent Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma TreatmentCabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort studyClinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active MelanomaBreast hormonal receptors test should be repeated on excisional biopsy after negative core needle biopsyHER2 testing: how to reach a high concordance rate between immunohistochemistry and fluorescence in situ hybridizationImmunotherapy Advances in Urothelial CarcinomaToxicities with targeted therapies after immunotherapy in metastatic melanomaAdvanced stage melanoma therapies: Detailing the present and exploring the futureQuantitative test-retest measurement of 68Ga-PSMA-HBED-CC (PSMA-11) in tumor and normal tissueIpilimumab-induced hypophysitis, a single academic center experienceCorrection to: Immunotherapy Advances in Urothelial CarcinomaDurable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse EventsIT-36PHASE 1/2 STUDY OF THE COMBINATION OF INDOXIMOD AND TEMOZOLOMIDE FOR ADULT PATIENTS WITH TEMOZOLOMIDE-REFRACTORY PRIMARY MALIGNANT BRAIN TUMORS
P50
Q30240751-5FBA313A-BBED-4E89-A0D6-EB6B9E6CBCA3Q34893987-DEDB8FBD-8B2B-46B2-BF3B-43DD02FE811AQ37021263-EF5B5FCB-8FF7-4C99-8E81-BDB6CE9D028EQ38230968-42D559E0-A846-4137-8790-9D1BF70A537AQ39003398-54EDE142-5D33-4506-BF76-C213905CFCC0Q39262556-49A4C358-0DFA-4D4C-8907-E76819232BECQ45833586-E05CDE6E-3208-4A44-8DAD-C49364EDDFBBQ46071137-C747A2E2-FF27-4023-BCE8-49B8B6C303ABQ48285831-F4EB3262-710F-4915-B269-A2800AF13D1FQ50123730-3EC7641B-80CB-479E-9371-8EF5510F5F12Q52726721-02AE428B-0C6F-4093-BA3B-DBD520E347A9Q57142019-4B039D70-513A-47E8-9936-B226B34260DEQ57159199-662F09CF-6755-45CD-9963-13F6FED22C9FQ57814400-4D4F0D6A-2642-4C42-8EAF-A8166D7169EAQ58750429-E8168CAB-8041-41A1-B333-B5CB049296A2Q58754086-4B6C1758-BD2F-4E51-AAE6-7F0993C88E2AQ60922626-977134E2-DC48-420C-BC22-CC826064CF8CQ64040149-A9DB77DA-6D93-4A71-A3AE-4AE65B00DF67Q64119823-861A23E6-B057-4E50-BFC5-3AD75246BAC1Q83391810-27E15D59-17E7-4FEE-96F3-5E5797C9C67FQ83566962-EB2CD8C2-3D28-48FC-B96D-3F73655FCE33Q90563299-1F0E4BDC-48C5-438F-98AC-B24BE0094849Q90815373-ECBB2C96-F173-4D63-B417-26A598700796Q91129002-BA09804E-5DDD-4E18-ADCA-82773E9380E4Q91735500-70B12618-64DC-4FEB-A639-0E18D286133BQ92052365-13CE036D-3808-4DDA-BFB0-ED08C4485FF3Q92231803-16EBFBE8-E4D5-474C-859C-CC7BA73BC1BAQ92712788-3B78E5E0-CC3E-4496-892D-EF5830F5BDD9Q94353501-BE53C6A2-8C05-4685-86B4-AACD2719FC5F
P50
description
researcher ORCID ID = 0000-0001-9480-2626
@en
name
Yousef Zakharia
@ast
Yousef Zakharia
@en
Yousef Zakharia
@es
Yousef Zakharia
@nl
type
label
Yousef Zakharia
@ast
Yousef Zakharia
@en
Yousef Zakharia
@es
Yousef Zakharia
@nl
prefLabel
Yousef Zakharia
@ast
Yousef Zakharia
@en
Yousef Zakharia
@es
Yousef Zakharia
@nl
P1153
37006074000
P31
P496
0000-0001-9480-2626